ClinicalTrials.gg

Program

edaglutide alfa

A development code. Also written as “TG103”, “TG103 22.5 mg” and “TG103 15 mg”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus, led by CSPC Pharmaceutical Group.

Furthest: phase 3, since Aug 8, 202311 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group110 open or runningphase 3since Aug 8, 2023Jun 12, 2019none ahead
  • Named in CSPC Pharmaceutical Group’s own pipeline as edaglutide alfa (TG103), phase 4, as of Aug 20, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 12, 2019First study: phase 1 study in HealthyFirst studyNCT03990090 · 32 enrolled · China
  2. Mar 3, 20212 phase 1 studiesNCT04790006, NCT04839744
  3. Apr 19, 2021Phase 1 study in Diabetes MellitusNCT04855292 · 48 enrolled · China
  4. Sep 14, 2021Phase 2 study in Diabetes Mellitus, Type 2NCT05063253 · 208 enrolled
  5. Mar 3, 2022Phase 2 study in OverweightNCT05299697 · 195 enrolled · China
  6. Apr 6, 2022Phase 2 study in Diabetes Mellitus, Type 2NCT05348122 · 240 enrolled · China
  7. Aug 8, 2023Phase 3 study in OverweightNCT05997576 · 675 enrolled · China
  8. Jan 11, 2024Phase 2 study in ObesityNCT06226090 · 314 enrolled · China
  9. Jan 23, 2024Phase 3 study in Diabetes Mellitus, Type 2NCT06235086 · 632 enrolled · China
  10. Feb 6, 2024Phase 3 study in Diabetes Mellitus, Type 2NCT06258148 · 465 enrolled · China

TargetBeta

“This study is a multicenter, randomized, double-blind, placebo-controlled, parallel phase II study to evaluate efficacy, safety, pharmacokinetics characteristics and immunogenicity of two dose levels of TG103 injection, a GLP-1 receptor agonist, in the management of overweight or obesity, to supp…”study summary, read by Claude · the study

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
survodutideBoehringer Ingelheimphase 335
zenagamtideNovo Nordiskphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
SafiglipronJiangsu HengRui Medicinephase 319

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06258148Diabetes Mellitus, Type 2 · China3CompletedJan 23, 2026465
NCT06235086Diabetes Mellitus, Type 2 · China3CompletedFeb 3, 2026632
NCT06226090Obesity · China2CompletedSep 26, 2024314
NCT05997576Overweight · China3CompletedFeb 17, 2025675
NCT05348122Diabetes Mellitus, Type 2 · China2UNKNOWNNov 1, 2023240
NCT05299697Overweight · China2UNKNOWNJun 30, 2023195
NCT05063253Diabetes Mellitus, Type 22UNKNOWNMar 2024208
NCT04855292Diabetes Mellitus · China1CompletedDec 1, 202248
NCT04839744Healthy Male Subjects · China1CompletedJun 15, 202124
NCT04790006Diabetes Mellitus, Type 21UNKNOWNMar 202254
NCT03990090Healthy · China1CompletedNov 11, 202032

How it is read

Names in the registry

  • “TG103”, 5 entries
  • “TG103 22.5 mg”, 3 entries
  • “TG103 15 mg”, 2 entries
  • “TG103 7.5 mg”, 1 entry
  • “TG103 injection”, 1 entry

Codes read as this program: TG103.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.